Star Combo Share Price Up 23.64% after Chinese Retailer Acquisition

By ,

The share price of Australian nutritional business, Star Combo Pharma Limited [ASX:S66], has rocketed up over 23% this morning. It has since calmed down a bit and is currently, at time of writing, up 7.5 cents to 62.5 cents per share.

S66 develops, manufactures and distributes a range of branded vitamins, dietary supplements and skincare products, serving both domestic and offshore markets. The company’s products are sold through several retailers including pharmacies and all Australian international airports.

Star Combo also sells its products internationally through its own website, as well as various online e-commerce platforms, such as Chinese giants Taobao and JD.

Star Combo secures Chinese retail channel

Star Combo shares were placed in a trading halt yesterday as the company brokered a deal to acquire the e-commerce platform Austoyou Group.

Austoyou is a fast-growing Australian-based platform that sells a wide range of products direct to Chinese consumers.

Star Combo also acquired Koala Mall Pty Limited, a supplier and distributer of vitamins and dietary supplements.

Free report: Aussie stock picker, Sam Volkering (with gains as high as 1,431% in the last 18 months) reveals what he believes are his next four big potential winners.

In a statement released this morning, Star Combo said the purchase of the businesses would be completed for $10 million.

CEO of Star Combo, Su Zhang, said the acquisitions advanced the evolution of the business…

These acquisitions are consistent with the Company’s listing strategy of acquiring an e-commerce platform that will advance the evolution of our business from a vitamin and supplements manufacturer and supplier to a fully integrated Australia – China health care company with manufacturing and multiple sales channels along with the expansion of our distribution networks.’

Australian nutritional and dietary supplements are in increasing demand by Chinese consumers. The Acquisition of Austoyou gives Star Combo a unique competitive advantage in this high-demand market.

What’s next for Star Combo?

By 2020, the market for vitamin and dietary supplements is expected to reach US$22.3 billion with a compounded annual growth rate pf 6.4% in the 2015–2020 period.

If the demand in growth continues, Star Combo should see those sales figures swell over the coming years.

But we should also expect to see more Australian health product suppliers target the Chinese market — and competing directly with Star Combo.

Blackmores Limited [ASX:BKL], for example, saw profits more than double in 2016 after increasing direct sales to China.

No doubt it will be difficult to compete with the larger players like Blackmores and Swisse, however, today’s acquisitions reflect Star Combo Chairman Richard Allely’s ambitions to emulate the success of the bigger players in China.


Ryan Clarkson-Ledward,
For Markets & Money

PS: Must read: Sam has already bagged 1,431% in the last 18 months. Could his next four picks be just as lucrative? Get access now (free).

About Ryan Clarkson-Ledward

Ryan Clarkson-Ledward is an Editor at Money Morning.

Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects.

Ryan is also the Editor…

Blackmores Share Price Down on Third Quarter Results

The latest news out of the company is the release of its third quarter results which reveal a 43% drop in profit. Blackmores has all the hallmarks of a ‘hold’ rating. 

Blackmores Drops 32% despite Solid Profit

Today’s first half results are reminiscent of Blackmores’ glory days of 2015 and 2016 when profits soared on the back of huge demand for high quality vitamins from Australia. Sadly, those days might be over.

Blackmores Share Price Rises on New Acquisition and Record Sales

Blackmores Limited [ASX:BKL] share price increased immediately upon opening, after revealing the acquisition of Probiotec Limited’s [ASX:PBP] IMPROMY brand and its record sales and profit growth.